Clinical Research Directory
Browse clinical research sites, groups, and studies.
Evaluation of YB-101 for Safety, Tolerability, Pharmacokinetics, and Efficacy in Graves' Disease
Sponsor: Yarrow Bioscience, Inc.
Summary
This study is being conducted to look at the effect YB-101 has on thyroid function. This study will also evaluate how safe and well tolerated YB-101 is and how it is distributed through the body. The study consists of a part 1, blinded treatment period, and a part 2 double-blinded treatment period. Participants will receive YB-101 or Placebo subcutaneously. Participants who participate in Part 1 can not participate in Part 2. Participants will complete 34-39 in-clinic visits in Part 1 or Part 2 over an approximate 40 week period.
Official title: A Randomized, Blinded, Placebo-Controlled, Two-Part, Phase 2 Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of YB-101 in Participants With Graves' Disease
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
232
Start Date
2026-06-10
Completion Date
2029-09
Last Updated
2026-09-04
Healthy Volunteers
No
Conditions
Interventions
Experimental: YB-101
YB-101 is administered over a 24 week period.
Placebo YB-101
Placebo will be administered over a 24 week period.
Locations (30)
Site 112
Gilbert, Arizona, United States
Site 130
Phoenix, Arizona, United States
Clinical Research Site
Tucson, Arizona, United States
Site 121
La Mesa, California, United States
Site 103
Sacramento, California, United States
Site 111
San Francisco, California, United States
Site 105
Torrance, California, United States
Site 109
Miami Lakes, Florida, United States
Site 115
Palm Harbor, Florida, United States
Site 123
Sarasota, Florida, United States
Site 118
Macon, Georgia, United States
Site 122
Bowling Green, Kentucky, United States
Site 126
Flint, Michigan, United States
Site 107
Livonia, Michigan, United States
Site 108
Omaha, Nebraska, United States
Site 129
Niagara Falls, New York, United States
Site 120
Orchard Park, New York, United States
Clinical Research Site
Raleigh, North Carolina, United States
Site 124
Sayre, Pennsylvania, United States
Site 100
Amarillo, Texas, United States
Site 117
Conroe, Texas, United States
Clinical Research Site
Dallas, Texas, United States
Site 128
Edinburg, Texas, United States
Site 127
El Paso, Texas, United States
Site 106
Fort Worth, Texas, United States
Site 110
Houston, Texas, United States
Site 101
Humble, Texas, United States
Site 116
San Antonio, Texas, United States
Site 151
East Melbourne, Victoria, Australia
Site 150
Melbourne N., Victoria, Australia